Earnings Releases·Nov 10, 2026, 4:30 PM ET

Intelligent Bio Solutions — Fiscal First Quarter 2027 Earnings Summary

Total revenue reached $1.39 million, a 25% year-over-year and 21% sequential increase, surpassing the prior record set in Q4 fiscal 2026.
Gross profit margin improved to 54.5% from 46.6% year-over-year, while the net loss narrowed to $2.66 million ($0.86 per share) from $2.98 million ($3.49 per share) in the prior-year quarter.
Management confirmed the company is well-positioned for continued growth through fiscal 2027, driven by recurring cartridge demand and plans to enter the U.S. drug screening market following FDA clearance.
The company submitted its 510(k) premarket notification to the FDA on September 9, 2026, for the Intelligent Fingerprinting Drug Screening System, with clinical data showing accuracy above 98%.
Cash and cash equivalents increased to $5.93 million as of September 30, 2026, up from $3.99 million in the prior quarter, while the installed base of readers grew to 1,978 units.